MCM
NVCR icon

Manchester Capital Management’s NovoCure NVCR Stock Holding History

Manchester Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-37
Closed -$479 – 1368
2025
Q4 		$479 Buy
+37
New +$475 ﹤0.01% 1267
2023
Q4 		– Sell
-5
Closed -$81 – 1054
2023
Q3 		$81 Hold
5
– – ﹤0.01% 1005
2023
Q2 		$208 Buy
+5
New +$310 ﹤0.01% 927
2021
Q1 		– Sell
-3
Closed -$1K – 739
2020
Q4 		$1K Hold
3
– – ﹤0.01% 671
2020
Q3 		$0 Buy
+3
New +$240 ﹤0.01% 646

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Manchester Capital Management's NVCR Position: Q1 2026 in Review

Manchester Capital Management sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 37 shares — an estimated $479 sold.

Manchester Capital Management first reported a position in NVCR in Q3 2020 and held it in 5 quarters. The position peaked at $1K in Q4 2020. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Manchester Capital Management reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
  • Manchester Capital Management sold 37 NovoCure shares in Q1 2026, an estimated $479.
  • Manchester Capital Management first reported a position in NovoCure in Q3 2020 and held it in 5 quarters.
  • Manchester Capital Management's NovoCure position peaked at $1K in Q4 2020.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.